收费全文 | 33772篇 |
免费 | 1923篇 |
国内免费 | 100篇 |
耳鼻咽喉 | 441篇 |
儿科学 | 2278篇 |
妇产科学 | 682篇 |
基础医学 | 4015篇 |
口腔科学 | 648篇 |
临床医学 | 2329篇 |
内科学 | 6644篇 |
皮肤病学 | 1049篇 |
神经病学 | 1754篇 |
特种医学 | 1240篇 |
外科学 | 5073篇 |
综合类 | 1016篇 |
一般理论 | 17篇 |
预防医学 | 1914篇 |
眼科学 | 1474篇 |
药学 | 2743篇 |
中国医学 | 143篇 |
肿瘤学 | 2335篇 |
2023年 | 203篇 |
2022年 | 462篇 |
2021年 | 970篇 |
2020年 | 526篇 |
2019年 | 686篇 |
2018年 | 949篇 |
2017年 | 623篇 |
2016年 | 852篇 |
2015年 | 768篇 |
2014年 | 1232篇 |
2013年 | 1475篇 |
2012年 | 2128篇 |
2011年 | 2288篇 |
2010年 | 1240篇 |
2009年 | 1047篇 |
2008年 | 1784篇 |
2007年 | 1834篇 |
2006年 | 1637篇 |
2005年 | 1613篇 |
2004年 | 1442篇 |
2003年 | 1343篇 |
2002年 | 1204篇 |
2001年 | 790篇 |
2000年 | 732篇 |
1999年 | 652篇 |
1998年 | 332篇 |
1997年 | 248篇 |
1996年 | 196篇 |
1995年 | 178篇 |
1994年 | 149篇 |
1993年 | 163篇 |
1992年 | 387篇 |
1991年 | 415篇 |
1990年 | 372篇 |
1989年 | 380篇 |
1988年 | 323篇 |
1987年 | 292篇 |
1986年 | 284篇 |
1985年 | 297篇 |
1984年 | 248篇 |
1983年 | 207篇 |
1982年 | 133篇 |
1979年 | 249篇 |
1978年 | 171篇 |
1977年 | 163篇 |
1976年 | 150篇 |
1975年 | 171篇 |
1974年 | 162篇 |
1973年 | 180篇 |
1972年 | 142篇 |
Background
Multiple myeloma (MM) is a hematologic malignancy of plasma cell origin. MM primarily affects bone marrow, but extramedullary sites can also be involved. Myelomatous pleural effusion (MPE) is an atypical and rare complication of MM. We aimed to systematically study the incidence and clinicopathologic profile of patients with MPE in a real-world setting.Patients and Methods
In this retrospective study, 415 consecutive patients with MM managed at a tertiary care center in North India during a study period of January 1, 2010 to December 31, 2015 were evaluated for MPE. The patients with MPE were analyzed for their clinical profile, diagnosis, treatment, and outcomes.Results
Of these 415 patients, 11 (2.65%) patients had MPE. The median age of the study population was 50 years with male preponderance. The majority of these patients had immunoglobin (Ig)G Kappa disease. All patients had higher than International Staging System stage I disease. MPE was a presenting feature at MM diagnosis in 45.45% (n = 5) of the patients, whereas the rest developed MPE during follow-up. MPE presented predominantly (81.8%) as a unilateral effusion. Concurrent extramedullary involvement at other site was seen in 45.45% (n = 5), with 3 (27%) patients having concurrent myelomatous ascites. Six of these were managed aggressively, whereas 5 patients opted for palliation. The outcomes were dismal (90.9% mortality), with a median survival of 2.47 months.Conclusion
MPE is a rare entity, and positive outcomes of therapy remain low with dismal prognosis. 相似文献Methods: A retrospective cohort design and data from two US healthcare claims repositories were employed. The study population included patients who had non-metastatic cancer of the breast, colon/rectum, lung or ovaries, or non-Hodgkin’s lymphoma (NHL), and who received myelosuppressive chemotherapy regimens with an intermediate/high risk for FN. For each patient, the first cycle of the first course was characterized in terms of PP-CSF use and FN episodes. Crude incidence proportions for PP-CSF and FN during the first cycle were estimated by calendar quarter (2010–2016); multivariable logistic regression models were used to estimate quarter-specific adjusted mean probabilities of FN by PP-CSF use.
Results: The study population totaled 142,730 patients with breast cancer (61%), colorectal cancer (14%), NHL (11%), ovarian cancer (10%) or lung cancer (5%). PP-CSF use increased from 52% in 1Q2010 to 58% in 4Q2016; pegfilgrastim was the most commonly used agent (>96% across quarters). PP-CSF administration on the same day as chemotherapy ranged from 8 to 11% until 1Q2015, and increased to 64% by 4Q2016. Adjusted incidence proportions for FN in the first chemotherapy cycle ranged from 2.7% (95% CI: 2.3–3.0) to 3.7% (95% CI: 3.1–4.3) among those who did not receive PP-CSF, and was 2.6% (95% CI: 2.5–2.7) across quarters among those who received PP-CSF.
Conclusions: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. 相似文献